According to Cognitive Market Research, the global Raxibacumab market size will be USD 101.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 14.20% from 2024 to 2031.
North America held the major market share for more than 40% of the global revenue with a market size of USD 40.60 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 30.45 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 23.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 16.2% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 5.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.6% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2.03 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2031.
The "Prevent Inhalational Anthrax" segment is the fastest-growing category, driven by increasing global emphasis on proactive biodefense strategies
